ALK and non-small cell lung carcinoma: The present analysis estimated the cost-effectiveness of camrelizumab plus chemotherapy vs. chemotherapy alone in first-line treatment of metastatic or advanced non-squamous NSCLC without targetable EGFR or ALK genetic aberrations in China based on data from NCT03134872.